Hepatitis B therapy (Q37855531)

24 August 2017

1 reference

title

Hepatitis B therapy (English)

1 reference

24 August 2017

1 reference

Hellan Kwon

1

1 reference

PubMed ID

21423260

24 August 2017

Anna S Lok

series ordinal

2

1 reference

PubMed ID

21423260

24 August 2017

language of work or name

English

0 references

publication date

22 March 2011

1 reference

Nature Reviews Gastroenterology & Hepatology

24 August 2017

1 reference

24 August 2017

8

1 reference

24 August 2017

275-284

1 reference

24 August 2017

5

1 reference

https://scigraph.springernature.com/pub.10.1038/nrgastro.2011.33

24 August 2017

0 references

cites work

Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005.

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Hepatitis B virus variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Telbivudine versus lamivudine in patients with chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Histological outcome during long-term lamivudine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Evolution of multi-drug resistant hepatitis B virus during sequential therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Fanconi syndrome and renal failure induced by tenofovir: a first case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

National Institutes of Health Consensus Development Conference Statement: management of hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Lamivudine for patients with chronic hepatitis B and advanced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Reactivation of hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection

21 January 2018

2 references

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

21 January 2018

12 December 2020

Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Lamivudine as initial treatment for chronic hepatitis B in the United States

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

Cytosolic phospholipase A2alpha and peroxisome proliferator-activated receptor gamma signaling pathway counteracts transforming growth factor beta-mediated inhibition of primary and transformed hepatocyte growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.33

HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C.

31 March 2020

1 reference

PubMed

12 December 2020

Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis

1 reference

PubMed

12 December 2020

Chronic hepatitis B: update 2009

1 reference

PubMed

12 December 2020

Identifiers

DOI

10.1038/NRGASTRO.2011.33

1 reference

24 August 2017

1 reference

PubMed ID

21423260